Navigation Links
Major NIMH research project to test approaches to altering the course of schizophrenia
Date:7/21/2009

of the trial, during which the investigators will refine the interventions with input from stakeholders and conduct a feasibility study to demonstrate that each intervention can be fielded in real world community treatment settings and be evaluated in a randomized clinical trial design. With long-term funds committed by NIMH to complete these phases plus a full-scale clinical trial, funding for the study is $40 million.

"Depending on the study's outcome, RAISE could help set the stage for a paradigm shift in the way schizophrenia is treated in the United States. The ultimate goal of the initiative is to eliminate the chronic form of schizophrenia that is so costly and devastating to the individual, family members, and society as a whole," said Robert Heinssen, Ph.D., acting director of the NIMH Division of Services and Intervention Research and project officer for RAISE. "This Recovery Act-supported project will hire and help train many mental health researchers and care providers for a project that is likely to help some of our most vulnerable citizens lead more productive and satisfying lives."

NIMH is using Recovery Act funds to carry out objectives identified in its Strategic Plan. Among these objectives is to develop new and better interventions that incorporate the diverse needs and circumstances of people with mental illnesses and to strengthen the public health impact of NIMH-supported research.


'/>"/>

Contact: Charlotte Armstrong
NIMHpress@nih.gov
301-443-4536
NIH/National Institute of Mental Health
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. 2009 National Ergonomics Conference Schedule Announced, Focus on Productivity & Profitability With Reduced Workforces, All Major Sponsors Renew & New Exhibitors Join the Expo
2. Avoiding Hysterectomy: Major Interventional Radiology E-collection Info Available
3. Celesio Acquires Majority Stake in Number One Brazilian Pharmaceutical Wholesaler Panpharma
4. Volcano Achieves Major Milestone in Japan Direct Sales Initiative With Signing of Termination Agreement With Goodman
5. Major Firms Eyeing CBMS Development of New Glaucoma Treatment
6. New Urine Drug Test to Detect for 6 Major Drugs, Now Available at Drugstore.com -- 'DrugConfirm' Is a New Revolutionary Urine Drug Test
7. Extreme Heat Causes Major Health Problems for Older Adults
8. Contract Talks for 1,800 Security Officers at Kaiser Permanente Break Down - Major Cuts to Worker Healthcare are at Issue
9. Nation Takes a Big Step Toward Learning Which Medical Treatments Work Best, a Major Advance in Fixing Our Broken Health-Care System
10. Major New Report Establishes Effective Methods of Enhancing and Preserving Brain Power as We Age
11. Major study highlights weight differences among 3-19 year-olds with type 1 and 2 diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...zlesmile,llc www.dazzlesmile.com andOptimalHealthS...67-pagefederallawsuitagainstEpicAdvertisingAKAAzoo...esLimited,andAtLastFulfillment.The13-countComplain...ictofUtah,allegesmassivenationalconsumerfraud,coun...oducts,violationsoftheRacketeeringInfluencedandCor...
(Date:11/25/2009)...roveOverallOutcomesforLungCancer ,, WASHINGTO...rAlliance-California(LCA-CA)issuedits2ndAnnual Rep...ntofprogressbeingmadeagainstthislethaldiseaseinthe...ance(LCA),theonlynationalorganizationdedicatedexcl...ithoratriskforlungcancer. ,, (Photo: http://www...
(Date:11/25/2009)...matology (ASH) is pleased to recognize the followi...bstracts in the categories of undergraduate studen...ysician, and post-doctoral,fellow. Merit Award wi...g,travel reimbursement. , The 2009 Merit Award ...imberly Fan , Donor Dendritic Cells Home to Lymph...
(Date:11/25/2009)... , An innovative treatment for HIV patients dev...ers has passed its first clinical trial with flyin...stomized for each individual patient, and was deve...e of the MUHC in collaboration with Dr. R. Skaly f...ade for the individual patient an "haute couture"...
(Date:11/25/2009)...atients with liver lesions, researchers find , ...ding the drug cetuximab to neoadjuvant chemotherap...ul surgery in colorectal cancer patients with inop...ests. , , Tumors spread to other parts of the ... cancer. Most commonly, the cancer spreads to the ...
Breaking Medicine News(10 mins):Health News:dazzlesmile Sues Epic Advertising and Jesse Willms 2Health News:Lung Cancer Alliance-California Releases 2nd Annual State-Specific Report Card On Lung Cancer 2Health News:ASH announces 2009 Merit Award winners 2Health News:Tailor-made HIV/AIDS treatment closer to reality 2Health News:Cetuximab Helps Treat Colorectal Cancer 2
... due to its First To File ... Pharmaceuticals Inc.,(RPI), a wholly owned subsid...ed today that RLL has received tentative approval ...Valsartan Tablets,were $1.3 billion (IMS - MAT: Ju...
...onal, Inc. (OTC. Bulletin Board: TCAR.OB) today an...er 24, 2007, with The Hain Celestial,Group, Inc. (...d and personal,care products company. Under the te...1, 2006, there were 7,454,582 shares of,TenderCare...
...ated, doing business as "Merge Healthcare" (Nasdaq...ical imaging software and services provider,announ...ced restatement of,its financial statements, the C... 2005, and 2006, as well as other,restated financi...
...RUSSIA, Pa., Oct. 29 Universal,Health Services, I...d net,income was $28.9 million, or $.54 per dilute...red to $113.9 million, or $2.00 per diluted share,...hare, as compared to $225.3 million, or $3.89 per ...
... that,global prices for most of its soy protein in...ding on the product line. The increase takes effec... Chairman Craig Binetti said, "Market conditions a...provide innovative, economical solutions." For se...
...; RO.S),a world-leading healthcare provider of pha...it has extended its offer to acquire all of the,ou..., Inc. (Nasdaq: VMSI ),to 5:00 p.m., New York Cit...her terms and conditions of the tender offer,remai...
Other Medicine News:Health News:Ranbaxy Receives Tentative Approval For Valsartan Tablets 2Health News:TenderCare International, Inc. Announces Signing of Merger Agreement with the Hain Celestial Group for All Outstanding Shares of TenderCare Stock 2Health News:Merge Healthcare Provides Update on the Restatement of Its Financial Statements 2Health News:Merge Healthcare Provides Update on the Restatement of Its Financial Statements 3Health News:Merge Healthcare Provides Update on the Restatement of Its Financial Statements 4Health News:Merge Healthcare Provides Update on the Restatement of Its Financial Statements 5Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 2Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 3Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 4Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 5Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 6Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 7Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 8Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 9Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 10Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 11Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 12Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 13Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 14Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 15Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 16Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 17Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 18Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 19Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 20Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 21Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 22Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 23Health News:Universal Health Services, Inc. Reports 2007 Third Quarter Earnings 24Health News:Solae Announces Global Price Increase for Soy Protein Ingredients 2Health News:Roche Extends Tender Offer for Ventana 2Health News:Roche Extends Tender Offer for Ventana 3Health News:Roche Extends Tender Offer for Ventana 4
(Date:11/25/2009)....25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: ABA...arebloodanalysissystems,announcedtodaythatClintSev...atthe21stAnnualPiperJaffrayHealthCareConferenceonW...illbeheldattheNewYorkPalaceHotelinNewYorkCity. ,...andmarketsportablebloodanalysissystemsforuseinanyv...
(Date:11/25/2009)...wswire-FirstCall/--NuVasive,Inc.(Nasdaq: NUVA ),am...inimallydisruptivesurgicaltreatmentsforthespine,an...November30,2009,at5:30p.m.ET/2:30p.m.PT.Theconfere...mentfortheCompany,sproductsandwillincludecommentsf...ion.Thedial-innumbersare1-877-407-4018fordomesticc...
(Date:11/25/2009)...swire/--Reportlinker.comannouncesthatanewmarketres...nasalDrugDelivery-USMarketTrends&Analysis htt...Delivery---US-Market-Trends--Analysis.html ,, ...ansionoftherapeuticapplicationsfromthedeliveryofco...emictherapeuticdrugs.Thefutureofthetechnologyhinge...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Sentry Data Systems Announces Claims Guardian 28TM 29 50150 1Sentry Data Systems Announces Claims Guardian 28TM 29 50150 2Sentry Data Systems Announces Claims Guardian 28TM 29 50150 3Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 1Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 2Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 3Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 4Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 5Brown Takes Over Reins as Chair of AOSSM Medical Publishing Board of Trustees 50148 1Brown Takes Over Reins as Chair of AOSSM Medical Publishing Board of Trustees 50148 2Brown Takes Over Reins as Chair of AOSSM Medical Publishing Board of Trustees 50148 3
...dy Comparing Leading Hepatitis C Therapies Provide...cal Practice, MILAN, Italy, April 26 Final resul..., clinical study comparing the,leading therapies f...e 43rd,Annual Meeting of the European Association ...tant insights that may help guide clinical practic...
...ts achieve undetectable HCV RNA levels following 4...egasys(R) plus Copegus(R) -, - Safety and tolerabi...ys plus Copegus - ...bsite -, - Conference call scheduled for Friday, A... and 7:00 PM CEST (Milan) -, PRINCETON, N.J. ...
Other Medicine Technology:Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 2Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 3Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 4Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 5Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 6
Ultra-Sensitive Testosterone EIA
...kes it possible to determine the,vitamin levels in...es all reagents in,ready to use form for preparati... the columns. ,The advantage of HPLC analytics is ...ngle test. The HPLC complete,system enables even l...
Steroid 21-Hydroxylase (21-OH) Autoantibody RIA
...st kit is intended for the quantitative determinat...eptionally sensitive ELISA procedure offers sensit...iding for accurate establishment of post-ablation ...l methods. Furthermore, with the ability to accura...
Medicine Products: